High failure rate in Pseudomonas aeruginosa-associated periprosthetic hip and knee joint infections
Ece Akcicek, Jennyfer A. Mitterer, Veronika Achatz, Tamino Szirmay, Sujeesh Sebastian, Jochen G. Hofstaetter
TL;DR
This study finds that Pseudomonas aeruginosa infections in hip and knee joint replacements have high failure rates and antibiotic resistance, making them difficult to treat.
Contribution
The study provides new insights into the prevalence, treatment challenges, and outcomes of Pseudomonas aeruginosa in periprosthetic joint infections.
Findings
Pseudomonas aeruginosa accounted for 3.1% of Gram-negative periprosthetic joint infections.
Success rates for treating these infections were only 46%, with reinfection-free survival dropping to 22.4% after 10 years.
Chronic infections required more revisions and showed increased antibiotic resistance over time.
Abstract
Introduction: Pseudomonas aeruginosa is one of the most common Gram-negative (GN) pathogens in periprosthetic joint infections (PJIs). However, not many data are available on them. This study aimed to evaluate the prevalence of P. aeruginosa in hip and knee PJIs, patient characteristics, types of infection, resistance patterns, treatments, and outcomes. Methods: We retrospectively analyzed culture-positive revision total hip and knee arthroplasties (rTHA and rTKA) from 2008 to 2023. Cases were evaluated according to the International Consensus Meeting (ICM) 2018 and European Bone and Joint Infection Society (EBJIS) criteria 2021. The success rate was calculated according to Tier classification. Results: Among 1640 revision procedures performed on 1286 patients, 195 revisions in 160 patients were positive for GN microorganisms, including 50 P. aeruginosa cases (3.1 %, hip/knee: 39/11) in…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3| Culture-positive revision TJA | |||
|---|---|---|---|
| (2008–2023) | |||
| Proc.: 1640 | |||
| Hip/knee: 971/669 | |||
| Pat.: 1286 | |||
|
| |||
| Positive revision TJA | |||
| Proc. (%): 50/1640 (3.1) | |||
| | Pat. (%): 38/1286 (3) | ||
| | Total | Hip | Knee |
| Proc: 50 | Proc: 39/50 (78 %) | Proc: 11/50 (22 %) | |
| | Pat: 38 | Pat: 28/38 (73.7 %) | Pat: 10/38 (26.3 %) |
| Male/female | 11/27 | 7/21 | 4/6 |
| Age in yrs. (avg |
|
|
|
| BMI (avg |
|
|
|
| UPIC (%) |
|
|
|
| Septic (%) |
|
|
|
| Acute PJI (%) | 13 (27.7) | 9 (19.2) | 4 (8.5) |
| Chronic PJI (%) | 34 (72.3) | 28 (59.6) | 6 (12.8) |
| Inf. Primary TJA (%) | 12 (25.5) | 7 (14.9) | 5 (10.6) |
| Inf. Revision TJA (%) | 35 (74.5) | 30 (63.8) | 5 (10.6) |
| Monomicrobial (%) | 37 (74) | 29 (58) | 8 (16.0) |
| Polymicrobial (%) | 13 (26) | 10 (20) | 3 (6.0) |
| ICM 2018 | |||
| Infected (%) | 40 (80) | 34 (68) | 6 (12) |
| Inconclusive (%) | 8 (16) | 4 (8) | 4 (8) |
| Not infected (%) | 2 (4) | 1 (2) | 1 (2) |
| EBJIS 2021 | |||
| Confirmed (%) | 36 (72) | 29 (58) | 7 (14) |
| Likely (%) | 14 (28) | 10 (20) | 4 (8) |
| Unlikely (%) | 0 (0) | 0 (0) | 0 (0) |
| Charlson CI, mdn |
|
|
|
| McPherson score | |||
| – Infection grade | |||
| I | 13 | 9 | 4 |
| II | 3 | 2 | 1 |
| III | 34 | 28 | 6 |
| – Systemic host grade | |||
| A | 13 | 10 | 3 |
| B | 29 | 22 | 7 |
| C | 8 | 7 | 1 |
| – Local extremity grade | |||
| 1 | 10 | 6 | 4 |
| 2 | 27 | 20 | 7 |
| 3 | 13 | 13 | 0 |
| Tier classification | |||
| 1 (%) | 15 (30) | 12 (24) | 3 (6) |
| 2 (%) | 0 (0) | 0 (0) | 0 (0) |
| 3 (%) | 18 (36) | 14 (28) | 4 (8) |
| 4 (%) | 17 (28) | 13 (26) | 4 (8) |
| Overall | Hip | Knee | ||||||
|---|---|---|---|---|---|---|---|---|
| Infected | Infected | UPIC | Infected | Infected | UPIC | |||
| primary | revision | primary | revision | |||||
| TJA | TJA | TJA | TJA | |||||
| Microbiologies total (%) | 225 (100) | 45 (20) | 133 (59.1) | 4 (1.8) | | 19 (8.4) | 17 (7.6) | 7 (3.1) |
| Tissue sample total (%) | 114 (50.6) | 19 (8.4) | 72 (32) | 0 (0) | 11 (4.9) | 6 (2.7) | 6 (2.7) | |
| Swab intraoperative (%) | 87 (38.7) | 21 (9.3) | 49 (21.8) | 4 (1.8) | 5 (2.2) | 8 (3.6) | 0 (0) | |
| Sonication total (%) | 24 (10.7) | 5 (2.2) | 12 (5.3) | 0 (0) | | 3 (1.3) | 3 (1.3) | 1 (0.4) |
| Total positive samples (%) | 177 (78.7) | 44 (19.6) | 100 (44.4) | 4 (1.8) | | 15 (6.7) | 9 (4) | 5 (2.2) |
| Pos. cultures for | 144 (64) | 44 (19.6) | 79 (35.1) | 4 (1.8) | | 8 (3.6) | 8 (3.6) | 1 (0.4) |
| Tissue sample (%) | 59 (26.2) | 19 (8.4) | 35 (15.6) | 0 (0) | 3 (1.3) | 1 (0.4) | 1 (0.4) | |
| Swab intraoperative (%) | 69 (30.7) | 20 (8.9) | 37 (16.4) | 4 (1.8) | 3 (1.3) | 5 (2.2) | 0 (0) | |
| Sonication (%) | 16 (7.1) | 5 (2.2) | 7 (3.1) | 0 (0) | | 2 (0.9) | 2 (0.9) | 0 (0) |
| Detected microorganism (%) | 200 (100) | 44 (22) | 111 (55.5) | 4 (2) | | 23 (11.5) | 9 (4.5) | 9 (4.5 |
| In monomicrobial (%) | 119 (59.5) | 44 (22) | 57 (28.5) | 4 (2) | 7 (3.5) | 7 (3.5) | (0) | |
| In polymicrobial (%) | 81 (35.5) | 0 (0) | 54 (27) | 0 (0) | | 16 (8) | 2 (1) | 9 (4.5) |
|
| 25 (12.5) | 0 (0) | 22 (11) | 1 (0.5) | 1 (0.5) | 1 (0.5) | ||
| Detected co-pathogens (%) | 56 (100) | 0 (0) | 32 (57.1) | 15 (26.8) | 1 (1.8) | 8 (14.3) | ||
|
| ||||||||
|
| 1 (1.8) | 1 (1.8) | ||||||
|
| 6 (10.7) | 6 (10.7) | ||||||
|
| 2 (3.6) | 2 (3.6) | ||||||
|
| 1 (1.8) | 1 (1.8) | ||||||
|
| 4 (7.1) | 4 (7.1) | ||||||
|
| 8 (14.3) | 8 (4) | ||||||
|
| ||||||||
|
| 2 (3.6) | 2 (3.6) | ||||||
|
| 6 (10.7) | 6 (10.7) | ||||||
|
| 6 (10.7) | 6 (10.7) | ||||||
|
| 2 (3.6) | 2 (3.6) | ||||||
|
| 1 (1.8) | 1 (1.8) | ||||||
|
| 4 (7.1) | 4 (7.1) | ||||||
|
| 1 (1.8) | 1 (1.8) | ||||||
|
| 2 (3.6) | 3 (1.5) | 2 (3.6) | |||||
|
| 3 (1.5) | 3 (1.5) | ||||||
|
| ||||||||
|
| 1 (1.8) | 1 (1.8) | ||||||
|
| 3 (1.5) | 3 (1.5) | ||||||
| Combination with first | Combination with second | Combination with third | Combination with fourth | |
|---|---|---|---|---|
| microorganism | microorganism | microorganism | microorganism | |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
| – | – | – |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| – |
|
|
|
|
|
|
| Surgical site | Revision 1 and resistances | Mono/poly | Treatment | Subsequent re-revision 1 and resistances | Mono/poly | Treatment | Subsequent re-revision 2 and resistances | Mono/poly | Treatment | Subsequent re-revision 3 and resistances | Mono/poly | Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rTHA | Single-stage | Mono | CIP | Two-stage | Mono | CIP | – | – | – | – | – | – |
|
| DAIR | Mono | TZP | Two-stage | Mono | MEM | DAIR R: CAZ, MEM, TZP, FEP | Mono | GEN | – | – | – |
|
| DAIR R: CAZ, MEM, TZP, IMP. | Poly | C/T | DAIR R: CAZ, MEM, TZP, IMP, | Mono | C/T | – | – |
| – | – |
|
|
| DAIR | Mono | MFX | DAIR | Mono | MFX | – | – | – | – | – | – |
|
| Spacer exchange | Mono | MFX | DAIR R: CIP, LVX | Mono | MEM | Two-stage R: | Mono | MEM | DAIR R: AZT, CIP, LVX. | Mono | MEM |
|
| Two-stage | Poly | CIP | DAIR R: | Mono | CIP | Two-stage R: | Mono | CIP*
| – | – | – |
|
| DAIR | Mono | CIP | DAIR | Mono | CIP | – | – | – | – | – | |
|
| DAIR | Poly | MEM | DAIR | Poly | MEM | – |
| – | — |
| |
| Mean time between revisions in days (SD) | – | 40.3 (50.5) | 23 (14.7) | 19 (0) |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsOrthopedic Infections and Treatments · Total Knee Arthroplasty Outcomes · Antimicrobial agents and applications
Introduction
1
Periprosthetic joint infections (PJIs) represent a severe complication following total joint arthroplasty (TJA). Gram-negative (GN) PJIs are on the rise, with the literature reporting incidences of up to 23 % (Hsieh et al., 2009; Sujeesh et al., 2018; Tattevin et al., 1999; Zimmerli et al., 2004). PJIs caused by GN organisms are considered more challenging due to their growing resistance to antibiotics, increased risk of subsequent re-revisions, and their presence in highly comorbid patients, which is linked to worse outcomes (Hsieh et al., 2009; Zmistowski et al., 2011).
Pseudomonas aeruginosa is an aerobic, biofilm-producing GN bacteria. It is identified as one of the most prevalent GN pathogens associated with hip and knee PJIs, accounting for approximately 20 %–40 % of cases (Hsieh et al., 2009; Lyczak et al., 2000; Rodríguez-Pardo et al., 2014; Zmistowski et al., 2011). Several studies have investigated P. aeruginosa-associated PJIs. Cerioli et al. (2020) emphasized the difficulty in treating implant-associated infections, which require prolonged intravenous and oral antibiotics. Kim et al. (2024) reported variable infection clearance rates after DAIR and two-stage revisions. Prié et al. (2022) observed favorable outcomes (82 %) in chronic, monomicrobial ciprofloxacin-susceptible PJIs treated with one-stage exchange, whereas Shah et al. (2016) found worse outcomes in patients managed with DAIR. Liu et al. (2025) noted that P. aeruginosa is not more difficult to treat than other GN bacteria in cases of acute infections when it is treated with DAIR. Although previous studies provide valuable insights into P. aeruginosa-associated PJIs, the results remain heterogeneous, limited by non-standardized outcome reporting tools and definitions with variable follow-up duration. Moreover, there is a paucity of data on whether antibiotic resistance can evolve in patients undergoing one or more subsequent re-revisions with P. aeruginosa-positive cultures.
The primary aim of this study was to analyze the prevalence of P. aeruginosa in hip and knee PJIs over a 16-year period. The secondary aims were to determine clinical characteristics, surgical interventions, the microbial spectrum of co-pathogens, antibiotic treatment, and changes in the antibiotic resistance patterns in patients undergoing subsequent P. aeruginosa-positive re-revisions and to assess the re-revision free survival.
Methods and materials
2
Study design and population
2.1
After the institution's research ethics board approval (EK 10/2020), a retrospective single-center analysis was conducted from our prospectively maintained arthroplasty and PJI databases. We analyzed a total of 1640 culture-positive hip and knee revision arthroplasties (rTHA/rTKA) performed on 1286 patients between January 2008 and December 2023. All patients who underwent septic or aseptic rTHA/rTKA with a positive intraoperative culture for P. aeruginosa were included for the final analysis.
Cases were classified based on the International Consensus Meeting (ICM) 2018 (Shohat et al., 2019) and the European Bone and Joint Infection Society (EBJIS) criteria (Mcnally et al., 2021). Patient-specific risk factors were evaluated using the McPherson classification (Coughlan and Taylor, 2020) and Charlson Comorbidity Index (CCI) (Roffman et al., 2016). PJIs were classified as acute or chronic based on onset of symptoms after primary or revision arthroplasty: acute if within 3 months and chronic if after 3 months (Zimmerli et al., 2004). Presumed aseptic revisions that yielded positive cultures from intraoperative samples were classified as unexpected positive intraoperative cultures (UPICs). Furthermore, infected cases were defined as infected primary TJA if the infection occurred after primary implantation or as infected revision TJA if the infection occurred after aseptic revision surgery.
Follow-up and clinical outcome
2.2
The mean follow-up time was months, after excluding the follow-up duration of the five patients who died within that period from the calculation. All subsequent re-revisions with a positive intraoperative culture of P. aeruginosa were included. Tier classification was used to access the clinical outcome at a minimum follow-up of 1 year and ranged from Tier 1 to 4. Infection control without the need for continued antibiotic therapy or subsequent re-revisions was classified as “Tier 1”. Continuous suppressive antibiotic treatment was designated as “Tier 2”, while any requirement for surgical intervention or spacer retention was defined as “Tier 3”. Mortality occurring within less than 1 year (4A) or more than 1 year (4B) from the initiation of PJI treatment was classified as “Tier 4” (Abblitt et al., 2019). Tier 1 and Tier 4B were accepted as successful as long as the death was unrelated to PJI.
Microbiological analysis
2.3
Routine microbiological analysis was conducted on periprosthetic tissue samples, intraoperative swabs, and implant sonication fluid during all revision surgeries. The median number of cultures obtained per surgery was 4.5 (range: 1–10) with a median number of two (range: 1–9) positive P. aeruginosa results. Swabs were considered positive cultures only when obtained intraoperatively. Explanted devices were immediately placed into sonication containers, to which saline solution was added to cover the implants completely. The container was then vortexed and sonicated. Periprosthetic tissue samples, intraoperative swabs, and sonication fluids (0.1 mL) were analyzed for bacteria and fungi using standard microbiological techniques, as described previously (Frank et al., 2021). Antimicrobial susceptibility profiling was determined using the BD system (Becton Dickinson and Company, Franklin Lakes, NJ) according to the manufacturer's recommendations and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines.
Statistical analysis
2.4
Continuous variables were assessed for normality using Shapiro–Wilk tests and presented as means ( ) standard deviations (SD) or medians (MD) with interquartile ranges (IQR), displayed as the first ( ) and third ( ) quartiles. Comparisons were performed using the Mann–Whitney test. Categorical variables were analyzed using the test of independence and Fisher's exact test. A binary logistic regression model was performed to identify independent predictors of treatment success. For all tests, a value of was considered significant. The Kaplan–Meier method was used to estimate reinfection-free survival rate with 95 % confidence intervals (CIs). Statistical analyses were performed with IBM, SPSS version 26.0 statistic software (SPSS Inc., Chicago, IL).
Results
3
Overall, 195/1640 (11.9 %; hip/knee: 139/56) procedures of 160/1286 (12.4 %) patients had a positive intraoperative culture for a GN pathogen. Of these, 50 revision arthroplasties (25.6 %, hip/knee: 39/11) performed on 38 patients (23.8 %, female/male: 27/11) yielded P. aeruginosa in intraoperative cultures and were included in the final analysis.
From 50 P. aeruginosa-positive procedures, 47 (94 %) of them were associated with PJI. Infections were acute in 13/47 cases (27.7 %) and chronic in 34/47 (72.3 %). Among these infections, 12/47 (25.5 %) procedures were infected primary TJAs and 35/47 (74.5 %) were infected revision TJAs. A total of 37 cases (74 %) were identified as monomicrobial, with the remaining 13 cases (26 %) being polymicrobial. P. aeruginosa was identified in three presumed aseptic revisions (6 %, hip/knee: 2/1). Detailed patient demographics, infection types, and classifications are presented in Table 1.
Microbiological analysis and co-infections
3.1
A total of 225 samples were obtained from 50 revision procedures, of which 177 (78.7 %) yielded a positive intraoperative culture. Among 144/177 positive cultures, P. aeruginosa was identified. Distributions of the microbiological spectrum are displayed in Table 2.
Among the 13 polymicrobial cases, intraoperative cultures identified two different pathogens in 9 cases (69.2 %), four pathogens in 1 case (7.7 %), and five pathogens in 3 cases (23.1 %). Proteus mirabilis was the most frequently observed pathogen in co-infections, found in 3 cases (23.1 %), all of which were rTHA. The distribution of concomitant microorganisms is shown in Table 3.
Poly- or monomicrobial infections had no significant impact on outcomes ( ). Polymicrobial cases were mostly chronic (9/13) and identified during rTHA (10/13) but showed no significant association with either rTHA ( ) or chronicity ( ).
Resistance pattern and treatment
3.2
No resistance to tobramycin was observed during antimicrobial susceptibility testing in all cases of culture-positive P. aeruginosa. The highest antibiotic resistance was observed among quinolones, with levofloxacin showing a resistance rate of 17.7 %, followed by piperacillin/tazobactam (15.2 %). The resistance rates of the tested antibiotics and their distribution within rTHA and rTKA are presented in Fig. 1. Multidrug-resistant Gram-negative bacteria (MDR-GNB) were detected in 5/50 cases (10 %).
*Antibiotic resistance percentages in Pseudomonas aeruginosa antibiograms in revision total hip and knee arthroplasties (AZT
aztreonam, CIP
ciprofloxacin, IMP
imipenem, TOB
tobramycin, AMI
amikacin, CAZ
ceftazidime, FEP
cefepime, LVX
levofloxacin, MEM
meropenem, TZP
piperacillin/tazobactam, COL
colistin).*
One patient experienced multiple recurrent episodes of PJI, including two episodes caused by P. aeruginosa, with a period of culture negativity between the episodes. Therefore, a total of 39 treatment procedures are described for 38 patients.
The most frequently employed treatment was a combination of ciprofloxacin and meropenem (13/39), with an average duration of 54.8 days (mean: 60.4 d, range: 15 to 140 d). This was followed by meropenem monotherapy (6/39), which had an average duration of 61.1 d. The remaining patients received heterogenous treatment combinations including piperacillin/tazobactam, imipenem, moxifloxacin, and gentamicin.
Two patients developed complications during their antibiotic therapy. The first patient, who was receiving meropenem and ciprofloxacin, developed leukopenia on postoperative day 46, leading to the discontinuation of ciprofloxacin. The second patient developed leukopenia on postoperative day 22 while receiving treatment with ciprofloxacin, piperacillin/tazobactam, and meropenem. All antibiotics were subsequently discontinued. Detailed durations and treatment modalities are available in the supplementary table.
Changes in the antibiotic resistance pattern during subsequent re-revisions
3.3
Multiple revisions with positive P. aeruginosa culture were identified in 8 (21.1 %) patients. All susceptibility changes were observed in cases of rTHA. The first patient received ceftolozane/tazobactam monotherapy, during which resistance to cefepime developed; concurrently, the patient was receiving caspofungin for the treatment of Candida dubliniensis infection. Meropenem monotherapy was administered to the second patient, who subsequently developed resistance to aztreonam. The third patient was likewise treated with meropenem monotherapy; resistance to ceftazidime, cefepime, meropenem, and piperacillin/tazobactam developed. The fourth patient received dual therapy with ciprofloxacin, imipenem, and piperacillin/tazobactam. Resistance initially developed to imipenem, followed by additional resistance to aztreonam, ciprofloxacin, meropenem, and piperacillin/tazobactam during continued ciprofloxacin and piperacillin/tazobactam therapy.
Polymicrobial infections were found in 3/8 patients. Table 4 provides detailed information on these patients, including the surgical site, the type of revision procedure performed, the type of infection, the time between revisions, and the changes observed in the resistance profile.
Surgical procedures and outcome
3.4
The revision surgeries comprised 18/50 (36 %) debridement, antibiotics, and implant retention (DAIR) procedures; 24 (48 %) two-stage revisions; five single-stage revisions (10 %); and three UPIC procedures (6 %). UPICs were identified in two aseptic stem/cup exchange procedures and in one single-stage revision performed due to mechanical complications. Two-stage revisions include resection arthroplasty and spacer implantation. Surgical procedures are detailed in Fig. 2.
*Surgical procedures that patients underwent for Pseudomonas PJI. Success rate calculated according to the MSIS Outcome Reporting Tool (MSIS ORT). Tier 1 and 4B accepted as successful. Proc/Pat
procedure count/patient count, TJA: total arthroplasty, FU: follow-up duration, SR: success rate, DAIR: debridement, antibiotics, and implant retention, UPIC: unexpected intraoperative cultures.*
Overall, the success rate was 46 % (23/50), considering only Tier 1 and 4B cases to be successful (15/50 Tier 1 and 8/50 Tier 4B). No cases were classified as Tier 2, while 18 were classified as Tier 3 and 9 as Tier 4A; all of these were considered failures. Of the 27 failed procedures (54 %), 4 were after rTKA and 23 were after rTHA. In septic cases, the highest success rate was achieved in single-stage procedures (4/5, 80 %), whereas two-stage procedures (10/24, 41.6 %) had the poorest outcome. Of the 18 cases treated with DAIR, 13 had chronic infections, with a success rate of 38.4 % (5/13), while 5 of them had acute infections with a success rate of 60 % (3/5). In the UPIC group, there was 1 failed case due to a septic complication, subsequently treated with resection arthroplasty.
A decrease in success rates was observed as the number of revision surgeries increased ( ). The median number of overall required revision surgeries was 5 (range: 1–13). A spacer retention or salvage-type procedure (resection arthroplasty: 13, amputation: 6) was required for infection control during follow-up in 19 of the 50 procedures. The number of chronic infections and total revisions was significantly higher in the re-revision group compared to the primary revision ( ). The infected revision group underwent an average of four subsequent revisions. Similarly, chronic infections were associated with a greater total number of revisions ( ), with an average of three additional procedures.
Figure 3 illustrates the reinfection-free survival probability over time. Median time was 85 months. The rate was 100 %, 85 %, 82 %, and 48 % following a 1-, 3-, 5-, and 10-year follow-up period.
Kaplan–Meier survival curve shows the reinfection-free survival probability after Pseudomonas aeruginosa-associated infection in revision total hip and knee arthroplasty.
Discussion
4
We analyzed data from 38 patients who underwent a total of 50 hip and knee revision arthroplasties with a positive intraoperative culture for P. aeruginosa. Overall, P. aeruginosa-associated PJIs presented with considerable complexity, showed changing antibiotic resistance patterns in patients with subsequent re-revisions, and were characterized by high rates of treatment failure. Remarkably, the majority of the cases were rTHA (78 %) and a significant proportion of these cases were infected revision TJAs, accounting for 70 %. Moreover, P. aeruginosa-associated PJIs were predominantly chronic and monomicrobial.
PJI cases caused by GN infection, including P. aeruginosa, have been mostly documented as acute and polymicrobial (Cerioli et al., 2020; Hsieh et al., 2009). However, our study mainly identified chronic and monomicrobial infections, similar to the findings of Prié et al. (2022). This observation may be related to the high proportion of revision TJAs within our cohort and aligns with the known strong biofilm-forming capacity of P. aeruginosa, which has been reported to hinder the detection of co-pathogens. Moreover, our study predominantly used conventional diagnostic methods, which, as previous studies have suggested, may preferentially detect fast-growing, dominant microorganisms. This may potentially mask slower-growing, anaerobic microorganisms that are difficult to culture, resulting in an underestimation of true polymicrobial diversity (Dhawan et al., 2016; Patnaik et al., 2025; Donlan, 2005; Trampuz et al., 2007).
Prior surgical interventions represent another key factor contributing to infection persistence (Frank et al., 2021; Mitterer et al., 2022; Siegert et al., 2023). Such prior procedures often compromise soft tissue quality, weaken the local immune response, and thereby increase susceptibility to PJI, particularly in revision TJAs (Zimmerli et al., 2004). Consistently, previous aseptic revisions have been associated with higher PJI incidence compared to primary TJAs (Lenguerrand et al., 2017). In line with this, our study showed that infected revision cases had a significantly higher incidence of chronic infection and greater total number of required revisions compared to revisions of primary TJAs. Our findings underline the persistent and recurrent nature of P. aeruginosa in PJIs, with multiple subsequent revisions with positive cultures.
Polymicrobial infections were most commonly observed in chronic cases and rTHA surgeries. Previous studies have also shown that polymicrobial infections and GN bacteria are more prevalent in rTHA than in rTKA (Stevoska et al., 2022; Tsai et al., 2019). These findings may be explained by differences in surgical exposure and soft tissue coverage. Furthermore, P. mirabilis was the most commonly observed co-pathogen in polymicrobial infections. This differs remarkably from other studies in which the dominant concomitant organisms were Staphylococcus aureus (Shah et al., 2016), GP cocci (Prié et al., 2022), and unspecified GP organisms (Kim et al., 2024). However, a recent study reported frequent concomitance of P. aeruginosa and Proteus mirabilis (Achatz et al., 2025). The high rate of rTHA in our study, along with the anatomical proximity of the urinary system to the hip joint and their shared vascular and lymphatic networks, may explain the frequent occurrence of concomitant P. mirabilis infections.
The most common treatment regimen was a combination of meropenem and ciprofloxacin. This therapeutic approach is consistent with the literature, which advocates for the use of a prolonged -lactam antibiotic, such as meropenem, in combination with ciprofloxacin for susceptible strains (Le Vavasseur and Zeller, 2022). Notably, fluoroquinolones are known to have the high rate of biofilm permeability and bactericidal activity, particularly against P. aeruginosa (Abdi-Ali et al., 2006). Among fluoroquinolones, ciprofloxacin is the only oral antibiotic with reliable activity against P. aeruginosa and the ability to penetrate the deeper layers of the biofilms (Anderl et al., 2000; Walters et al., 2003). This is supported by a recent study, which found that a minimum of 3 months of ciprofloxacin monotherapy was associated with improved outcomes (Cerioli et al., 2020). However, other studies did not observe any significant superiority among various antibiotic regimens (Shah et al., 2016; Tekes-Manuva et al., 2024). In our study, significance testing was not performed due to heterogeneous antibiotic regimens, precluding direct comparison with these findings. Nevertheless, the high failure rate observed in our cohort suggests that achieving reliable treatment success in P. aeruginosa PJI remains a persistent challenge despite existing recommendations.
Two-stage procedure is recommended for patients with chronic PJIs, compromised soft tissue conditions, and/or infections caused by DTR (difficult-to-treat) microorganisms (Zimmerli et al., 2004). In our study, the majority of procedures were performed as two-stage revisions, reflecting the high prevalence of chronic infections. Although P. aeruginosa is generally considered to be a DTR pathogen, a recent study by Liu et al. (2025) suggests that early acute PJI caused by P. aeruginosa does not present greater treatment challenges than other GN PJIs when treated with DAIR. However, previous studies have shown high DAIR failure rates for chronic GN infections (Duque et al., 2017; Zhu et al., 2021). According to the latest EBJIS recommendations (Sigmund et al., 2025), DAIR should not be performed in cases of chronic infection. However, due to the retrospective design of this study, the included DAIR procedures were performed on a case-by-case basis by the surgeon, taking into account the patient's condition and the surgeon's preference before standardized in-house protocols were established.
An adequate follow-up period is essential for accurately capturing changes in resistance patterns and outcomes, as short follow-ups may fail to detect late microbiological shifts, low-grade infections with failed infection control, or persistent infections with undetected pathogens. To our knowledge, this is the first study reporting changes in antibiotic resistance patterns in patients with more than one culture-positive P. aeruginosa re-revision with a long follow-up. Previous studies have described microbial profile and resistance changes during up to one following re-revision or two-stage exchange procedure in a non-microorganism-specific manner and focusing on other implant-related infections (Akgün et al., 2017; Frank et al., 2021; Kim et al., 2024; Kurd et al., 2010; Mitterer et al., 2022; Tan et al., 2016). Since changes in microbial resistance may lead to treatment failure (Frank et al., 2021), comprehending the microorganism-specific resistance dynamics in chronic hip and knee infections with long-term follow-up is essential.
Given the retrospective design of our study, several limitations must be acknowledged. This study includes data before a standardized in-house protocol for intraoperative sample harvesting was established, resulting in a relatively high number of swabs used for microbiological analysis. This may have led to variations and inaccuracies in pathogen identification. However, we only accepted swabs taken intraoperatively as a diagnostic tool until 2018. Additionally, defining success based on surgical outcomes does not reflect patients' clinical complaints, quality of life, and overall health status. Furthermore, as our study is single-centered, it may be influenced by specific patient demographics, comorbidities, and local antibiotic resistance patterns. Due to the small cohorts in subgroup analyses, the statistical power may be limited; therefore results should be interpreted with caution.
Conclusion
5
In conclusion, P. aeruginosa-related PJIs are common among GN PJIs and clinically challenging due to their high failure rate. Our findings show that PJIs associated with P. aeruginosa occur primarily in infected revision hip arthroplasties and are usually chronic and monomicrobial. Infection duration and total revision count significantly affect the clinical outcomes. Changes in antibiotic resistance patterns in patients with subsequent P. aeruginosa-positive re-revisions highlight the necessity of comprehensive diagnostics and reflect the limitation of treatment options in achieving successful infection control in P. aeruginosa-associated PJIs.
Supplement
10.5194/jbji-11-83-2026-supplementThe supplement related to this article is available online at https://doi.org/10.5194/jbji-11-83-2026-supplement.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Abblitt WP Ascione T Bini S Bori G Brekke AC Chen AF Courtney PM Della Valle CJ Diaz-Ledezma C Ebied A Fillingham YJ Gehrke T Goswami K Grammatopoulos G Marei S Oliashirazi A Parvizi J Polkowski G Saeed K Schwartz AJ Segreti J Shohat N Springer BD Suleiman LI Swiderek LK Tan TL Yan CH Zeng YR Hip and Knee Section, Outcomes: Proceedings of International Consensus on Orthopedic Infections J Arthroplasty 34S 487S 49510.1016/j.arth.2018.09.035201930348557 · doi ↗ · pubmed ↗
- 2Abdi-Ali A Mohammadi-Mehr M Agha Alaei Y Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa Int J Antimicrob Agents 2719620010.1016/J.IJANTIMICAG.2005.10.007200616459057 · doi ↗ · pubmed ↗
- 3Achatz V Mitterer JA Huber S Akcicek E Tobudic S Sebastian S Hofstaetter JG Proteus-species-associated periprosthetic hip and knee joint infections – a 15-year cohort analysis J Bone Joint Infect 1026527510.5194/jbji-10-265-20252025 PMC 1234559240808746 · doi ↗ · pubmed ↗
- 4Akgün D Müller M Perka C Winkler T Positive bacterial culture during re-implantation is associated with a poor outcome in two-stage exchange arthroplasty for deep infection Bone Joint J 99-B 1490149510.1302/0301-620X.99B 11.BJJ-2017-0243-R 1201729092988 · doi ↗ · pubmed ↗
- 5Anderl JN Franklin MJ Stewart PS Role of Antibiotic Penetration Limitation in Klebsiella pneumoniae Biofilm Resistance to Ampicillin and Ciprofloxacin Antimicrob Agents Chemother 441818182410.1128/aac.44.7.1818-1824.2000200010858336 PMC 89967 · doi ↗ · pubmed ↗
- 6Cerioli M Batailler C Conrad A Roux S Perpoint T Becker A Triffault-Fillit C Lustig S Fessy MH Laurent F Valour F Chidiac C Ferry T Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France Front Med (Lausanne)751324210.3389/fmed.2020.513242202033195289 PMC 7649271 · doi ↗ · pubmed ↗
- 7Coughlan A Taylor F Classifications in Brief: The Mc Pherson Classification of Periprosthetic Infection Clin Orthop Relat Res 47890390810.1097/CORR.0000000000001133202031977434 PMC 7282566 · doi ↗ · pubmed ↗
- 8Dhawan B Sebastian S Malhotra R Kapil A Gautam D Prosthetic joint infection due to Lysobacter thermophilus diagnosed by 16S r RNA gene sequencing Indian J Med Microbiol 3410010210.4103/0255-0857.174124201626776130 · doi ↗ · pubmed ↗